Compare PW & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | PPBT |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.4M |
| IPO Year | 2011 | 2014 |
| Metric | PW | PPBT |
|---|---|---|
| Price | $6.62 | $1.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.3K | ★ 27.3K |
| Earning Date | 11-06-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,982,265.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.32 | N/A |
| 52 Week Low | $0.50 | $0.41 |
| 52 Week High | $12.92 | $5.18 |
| Indicator | PW | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 68.34 |
| Support Level | $6.41 | $1.39 |
| Resistance Level | $7.22 | $1.60 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 76.09 | 91.78 |
Power REIT is an internally-managed real estate investment trust that owns a portfolio of real estate assets related to transportation, energy infrastructure and Controlled Environment Agriculture in the United States. Its assets consisted of approximately 112 miles of railroad infrastructure and related real estate which is owned by its subsidiary, approximately 447 acres of fee simple land leased to a utility scale solar power generating project with an aggregate generating capacity of approximately 82 Megawatts and approximately 82 acres of land with approximately 357,000 square feet of CEA properties in the form of greenhouses. The company invested in greenhouses for state-licensed cannabis and food cultivation.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.